Proactive Investors - Run By Investors For Investors

Faron Pharma to expand its Clevegen trial to focus on Colorectal cancer

Faron Pharmaceuticals Ltd's (LON:FARN) chief executive Markku Jalkanen tells Proactive London's Andrew Scott they're to target more patients with late-stage colorectal cancer as part of the ongoing phase I/II study of its Clevegen immunotherapy drug.

One of the patients currently enrolled in the trial has the most common form of colorectal cancer – called MSI-low – and has seen a “significant shrinkage” in lung metastasis.

The cohort expansion stage is planned for later this year once the optimal dose has been identified.

View full FARN profile View Profile

Faron Pharmaceuticals Ltd Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use